CLRB News and Press, Cellectar Biosciences Inc. From 09/14/20

Our analysis concludes CLRB appears a worthwhile speculative investment at $1.15 per share primarily because the potential upside dramatically outweighs the risk of downside based on, among other things, the results of CLRB's Phase 2 trial (called CLOVER-1) of its CLR131 candidate therapy in p...

Intra-Cellular stock jumps as its bipolar trial delivers positive data Intra-Cellular Therapies Inc. (ITCI) announced positive top-line data from its Phase 3 clinical trial of its lead drug candidate lumateperone. The trial was designed to evaluate the potential of lumateperone as an ad...

FLORHAM PARK, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced James Caruso, president and CE...

Cellectar Biosciences ( CLRB +2.8% ) announced that a clinically meaningful 40% (6/15 patients) overall response rate (ORR) was observed in the CLOVER-1 Phase 2 study for CLR 131, in the subset of multiple myeloma (MM) patients, deemed triple class refractory who received ...

FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that a clinically meaningful 4...

Poster highlights the Phase 2a study data in relapsed or refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM) Interim results show 100% overall response rate and a 75% major response rate FLORHAM PARK, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Cell...

CureVac (NASDAQ: CVAC ) +47%  on making reasonable profit on COVID-19 vaccine. More news on: CureVac N.V., LMP Automotive Holdings, Inc., Microbot Medical Inc., Stocks on the move, , Read more ...

These Names Are On Analysts’ Lists Of Penny Stocks Right Now; Are They On Yours? Penny stocks aren’t just “short-term” movers or “lotto trades” as some might assume. If you’ve been a reader of our articles this year, you have come to learn tha...

Cellectar Biosciences (NASDAQ: CLRB ) : Q2 GAAP EPS of -$0.26 beats by $0.04 . More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the secon...